Elisabetta Bianchi
30Patents
4h-index
93Co-inventors
66Inventor score
Filing activity: Nov 8, 1990 → Sep 27, 2022
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7928058B2 | Pharmaceutical composition comprising oxyntomodulin derivatives and a method for reducing body weight using the composition | Human Necessities | 23 | Active |
| US8969294B2 | Glucagon/GLP-1 receptor co-agonists | Human Necessities | 15 | Active |
| US5196512A | Synthetic peptides useful as universal carriers for the preparation of immunogenic conjugates and their use in the development of synthetic vaccines | Emerging Cross-Sectional Technologies | 6 | Expired |
| US11530244B2 | Cyclic polypeptides for PCSK9 inhibition | Human Necessities | 4 | Active |
| US6197536A | Methodology to produce, and purify and assay polypeptides with the proteolytic activity of the HCV NS3 protease | Chemistry; Metallurgy | 2 | Expired |
| US8629101B2 | Cholesterol derivatives of inhibitors of viral fusion | Emerging Cross-Sectional Technologies | 2 | Active |
| US7811577B2 | Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity | Physics | 2 | Active |
| US9593155B2 | Oxyntomodulin analogs | Human Necessities | 1 | Active |
| US8268779B2 | Pharmaceutical composition comprising oxyntomodulin derivatives and a method for reducing body weight using the composition | Human Necessities | 1 | Active |
| US11427616B2 | PCSK9 antagonist compounds | Human Necessities | 1 | Active |
| US7744887B2 | Human antibodies interacting with HIV gp41 | Physics | 1 | Expired |
| US10961295B2 | Modified lipidated Relaxin B chain peptides and their therapeutic use | Human Necessities | 1 | Active |
| US10988524B2 | Modified relaxin B chain peptides and their therapeutic use | Human Necessities | 1 | Active |
| US10988523B2 | Modified lipidated Relaxin B chain peptides and their therapeutic use | Human Necessities | 1 | Active |
| US6995177B1 | HCV NS3 protease inhibitors | Chemistry; Metallurgy | 1 | Expired |
| US11306125B2 | PCSK9 antagonists bicyclo-compounds | Human Necessities | 0 | Active |
| US11505575B2 | Cyclic polypeptides for PCSK9 inhibition | Human Necessities | 0 | Active |
| US11932705B2 | Cyclic polypeptides for PCSK9 inhibition | Human Necessities | 0 | Active |
| US11492385B2 | Long-acting co-agonists of the glucagon and GLP-1 receptors | Human Necessities | 0 | Active |
| US10493125B2 | Co-agonists of the glucagon and GLP-1 receptors | Human Necessities | 0 | Active |
| US11773150B2 | Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors | Chemistry; Metallurgy | 0 | Active |
| US12209145B2 | PCSK9 antagonist compounds | Human Necessities | 0 | Active |
| US10800826B2 | Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors | Chemistry; Metallurgy | 0 | Active |
| US10413593B2 | Co-agonists of the glucagon and GLP-1 receptors | Chemistry; Metallurgy | 0 | Active |
| US11725036B2 | Modified lipidated relaxin B chain peptides and their therapeutic use | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.